Clinical impact of
99mTc-MAA scintigraphy
Hepatocellular carcinoma
Selective Internal RadioTherapy
Transarterial radioembolization
Journal
European journal of hybrid imaging
ISSN: 2510-3636
Titre abrégé: Eur J Hybrid Imaging
Pays: England
ID NLM: 101724113
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
09
04
2023
accepted:
22
06
2023
medline:
7
7
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
Recent data demonstrated that personalized dosimetry-based selective internal radiotherapy (SIRT) is associated with better outcome for unresectable hepatocellular carcinoma (HCC). We aim to evaluate the contribution of personalized predictive dosimetry (performed with Simplicity This is a retrospective, single-center study conducted between February 2016 and December 2020 that included patients with HCC who received SIRT after simulation based on either standard dosimetry (group A) or, as of December 2017, on personalized dosimetry (group B). Primary endpoints were best overall response (BOR) and objective response rate (ORR) evaluated by mRECIST at 3 months. Safety and toxicity profiles were evaluated at 1- and 3-months post-treatment. For group A we compared the activity to be administered determined a posteriori using Simplicit Between February 2016 and December 2020, 66 patients received 69 simulations leading to 40 treatments. The median follow-up time was equal for both groups, 21 months (range 3-55) in group A and 21 months (range 4-39) in group B. The per patient analysis revealed a significant benefit of personalized predictive dosimetry in terms of better overall response at 3 months (80% vs. 33.3%, p = 0.007) and at 6 months (77.8% vs. 22.2%, p = 0.06). This trend was found in the analysis by nodule with a response rate according to mRECIST of 87.5% for personalized dosimetry versus 68.4% for standard dosimetry at 3 months, p = 0.24. Only one grade 3 biological toxicity (hyperbilirubinemia) was noted in group A. The comparison between the administered activity and the recommended activity recalculated a posteriori using Simplicit Our study aligns to recent literature and confirms that the use of personalized dosimetry allows a better selection of HCC patients who can benefit from SIRT, and consequently, improves the effectiveness of this treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Recent data demonstrated that personalized dosimetry-based selective internal radiotherapy (SIRT) is associated with better outcome for unresectable hepatocellular carcinoma (HCC).
AIM
OBJECTIVE
We aim to evaluate the contribution of personalized predictive dosimetry (performed with Simplicity
METHODS
METHODS
This is a retrospective, single-center study conducted between February 2016 and December 2020 that included patients with HCC who received SIRT after simulation based on either standard dosimetry (group A) or, as of December 2017, on personalized dosimetry (group B). Primary endpoints were best overall response (BOR) and objective response rate (ORR) evaluated by mRECIST at 3 months. Safety and toxicity profiles were evaluated at 1- and 3-months post-treatment. For group A we compared the activity to be administered determined a posteriori using Simplicit
RESULTS
RESULTS
Between February 2016 and December 2020, 66 patients received 69 simulations leading to 40 treatments. The median follow-up time was equal for both groups, 21 months (range 3-55) in group A and 21 months (range 4-39) in group B. The per patient analysis revealed a significant benefit of personalized predictive dosimetry in terms of better overall response at 3 months (80% vs. 33.3%, p = 0.007) and at 6 months (77.8% vs. 22.2%, p = 0.06). This trend was found in the analysis by nodule with a response rate according to mRECIST of 87.5% for personalized dosimetry versus 68.4% for standard dosimetry at 3 months, p = 0.24. Only one grade 3 biological toxicity (hyperbilirubinemia) was noted in group A. The comparison between the administered activity and the recommended activity recalculated a posteriori using Simplicit
CONCLUSIONS
CONCLUSIONS
Our study aligns to recent literature and confirms that the use of personalized dosimetry allows a better selection of HCC patients who can benefit from SIRT, and consequently, improves the effectiveness of this treatment.
Identifiants
pubmed: 37414964
doi: 10.1186/s41824-023-00171-8
pii: 10.1186/s41824-023-00171-8
pmc: PMC10326228
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12Informations de copyright
© 2023. The Author(s).
Références
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Eur J Nucl Med. 1997 Mar;24(3):293-8
pubmed: 9143467
J Hepatol. 2022 Apr;76(4):874-882
pubmed: 34856322
Med Phys. 2022 Dec;49(12):7567-7582
pubmed: 35894818
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699
pubmed: 35146577
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75
pubmed: 26338177
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):798-806
pubmed: 31399801
J Nucl Med. 2016 Nov;57(11):1672-1678
pubmed: 27307346
J Nucl Med. 2015 Nov;56(11):1654-60
pubmed: 26315830
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1695-1704
pubmed: 31098749
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29
pubmed: 33166497
Br J Radiol. 1997 Aug;70(836):823-8
pubmed: 9486047
Med Phys. 2011 Aug;38(8):4824-45
pubmed: 21928655
J Nucl Med. 2013 Apr;54(4):516-22
pubmed: 23447653
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584
pubmed: 33433699
Eur J Nucl Med. 1999 Jul;26(7):699-704
pubmed: 10398817
Liver Int. 2017 Jan;37(1):101-110
pubmed: 27514012
J Nucl Med. 2013 Aug;54(8):1294-301
pubmed: 23749996
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Radiology. 2020 Sep;296(3):673-684
pubmed: 32602828
J Vasc Interv Radiol. 2015 Nov;26(11):1615-21
pubmed: 26321017
Hepatology. 2021 Nov;74(5):2342-2352
pubmed: 33739462
Biomaterials. 2001 Nov;22(22):3073-81
pubmed: 11575483